Document is current
Any future updates will be listed below
-
Authors
Ashton, Nicholas J. https://orcid.org/0000-0002-3579-8804
Janelidze, Shorena
Al Khleifat, Ahmad https://orcid.org/0000-0002-7406-9831
Leuzy, Antoine
van der Ende, Emma L.
Karikari, Thomas K. https://orcid.org/0000-0003-1422-4358
Benedet, Andrea L.
Pascoal, Tharick A.
Lleó, Alberto https://orcid.org/0000-0002-2568-5478
Parnetti, Lucilla
Galimberti, Daniela https://orcid.org/0000-0002-9284-5953
Bonanni, Laura
Pilotto, Andrea
Padovani, Alessandro
Lycke, Jan https://orcid.org/0000-0002-7891-8466
Novakova, Lenka
Axelsson, Markus
Velayudhan, Latha https://orcid.org/0000-0002-7712-930X
Rabinovici, Gil D.
Miller, Bruce
Pariante, Carmine https://orcid.org/0000-0002-9132-5091
Nikkheslat, Naghmeh
Resnick, Susan M.
Thambisetty, Madhav
Schöll, Michael https://orcid.org/0000-0001-7800-1781
Fernández-Eulate, Gorka https://orcid.org/0000-0003-1112-7464
Gil-Bea, Francisco J.
López de Munain, Adolfo
Al-Chalabi, Ammar https://orcid.org/0000-0002-4924-7712
Rosa-Neto, Pedro
Strydom, Andre
Svenningsson, Per
Stomrud, Erik
Santillo, Alexander
Aarsland, Dag
van Swieten, John C.
Palmqvist, Sebastian https://orcid.org/0000-0002-9267-1930
Zetterberg, Henrik https://orcid.org/0000-0003-3930-4354
Blennow, Kaj https://orcid.org/0000-0002-1890-4193
Hye, Abdul
Hansson, Oskar https://orcid.org/0000-0001-8467-7286
- License Information
-
More Information
Article History
Received: 21 August 2020
Accepted: 4 May 2021
First Online: 7 June 2021
Competing interests
: J.L. has received travel support and/or lecture honoraria from Biogen, Novartis, Merck, Roche, and Sanofi Genzyme; has served on scientific advisory boards for Biogen, Novartis, Merck, Alexion, Roche, and Sanofi Genzyme; serves on the editorial board of the Acta Neurologica Scandinavica; has received unconditional research grants from Biogen and Novartis. A.A.C. has served as a consultant or on advisory boards for Amylyx, Apellis, Biogen Idec, Brainstorm, Cytokinetics, GSK, Lilly, Mitsubishi Tanabe Pharma, Novartis, OrionPharma, Quralis, and Wave Pharmaceuticals. A.S. has been a consultant for AC-Immune and is a member of the scientific advisory board of ProMIS Neurosciences. P.S. has received speaker fees for Shire/Takeda and Sanofi Genzyme. H.Z. has served at scientific advisory boards for Denali, Roche Diagnostics, Wave, Samumed, and CogRx; has given lectures in symposia sponsored by Alzecure and Biogen; and is a co-founder of Brain Biomarker Solutions in Gothenburg AB, a GU Ventures-based platform company at the University of Gothenburg. K.B. has served as a consultant or at advisory boards for Alector, Alzheon, CogRx, Biogen, Lilly, Novartis, and Roche Diagnostics, and is a co-founder of Brain Biomarker Solutions in Gothenburg AB, a GU Venture-based platform company at the University of Gothenburg, all unrelated to the work presented in this paper. O.H. has acquired research support (for the institution) from Roche, GE Healthcare, Biogen, AVID Radiopharmaceuticals, and Euroimmun. In the past 2 years, he has received consultancy/speaker fees (paid to the institution) from Biogen and Roche. The remaining authors declare no competing interests.
